We are live on ! Find out more
RGN

REGENERX BIOPHARMACEUTICALS
RGN

Delisted

RGN was delisted on the 22nd of December, 2010.

Back to rankings

2 hedge funds and large institutions have $34K invested in REGENERX BIOPHARMACEUTICALS in 2018 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

11% less capital invested

Capital invested by funds: $38K → $34K (-$4K)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
WJA
1
Williams Jones & Associates
New York
$30K – – –
DBIA
2
Dumont & Blake Investment Advisors
New Jersey
$4K – – –

RGN Hedge Fund Activity: Q2 2018 in Review

2 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q2 2018, worth a combined $34K — down 11% from $38K a quarter earlier.

Fund positioning in RGN was balanced in Q2 2018: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 2 institutional investors held REGENERX BIOPHARMACEUTICALS (RGN) as of Q2 2018, unchanged from Q1 2018.
  • Funds reported $34K of REGENERX BIOPHARMACEUTICALS stock for Q2 2018, down 11% quarter-over-quarter.
  • 0 funds opened new REGENERX BIOPHARMACEUTICALS positions in Q2 2018 and 0 closed out.

Based on aggregated 13F filings for Q2 2018.